Abstract

Objectives: To evaluate the prevalence of persistent lipid abnormalities and statin use in Chinese patients with coronary artery disease. Methods: This cross-sectional observational study consecutively enrolled 9420 outpatients with coronary artery disease in China. ESC/EAS Guidelines for the management of dyslipidemia and Chinese guidelines on prevention and treatment of dyslipidemia in adults were used to compare the control rate of low density lipoprotein cholesterol, high density lipoprotein cholesterol and triglyceride. Results: Among the 9420 participants, 33.6% was diagnosed as diabetes mellitus. The percentage of patients with not-at-goal LDL cholesterol was significantly lower in patients with diabetes than those without diabetes (72.7% vs 73.2%, P<0.001). The corresponding values for HDL-C and TG were 42.9% vs 34.2% (P<0.001) and 40.6% vs 35.2% (P<0.001), respectively. Only about 10% patients had optimal LDL-C, HDLC and TG. Compared with patients without DM, patients with DM were more likely to have mixed dyslipidemia. Atorvastatin (47.0%) and simvastatin (34.4%) were the two most frequently used statin and the average statin dosage was 29.09 mg/d (simvastatin equivalent). Drug combination with statin to modulate lipid was only 3%. Conclusions: Although international guideline highly recommends intensive lipid modification in patients with coronary artery disease, persistent dyslipidemia was still prevailing in China, even with statin treatment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.